IL288755A - Compositions and methods for biological delivery vehicles - Google Patents
Compositions and methods for biological delivery vehiclesInfo
- Publication number
- IL288755A IL288755A IL288755A IL28875521A IL288755A IL 288755 A IL288755 A IL 288755A IL 288755 A IL288755 A IL 288755A IL 28875521 A IL28875521 A IL 28875521A IL 288755 A IL288755 A IL 288755A
- Authority
- IL
- Israel
- Prior art keywords
- preparations
- methods
- biological substances
- delivery carriers
- carriers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
- A61K47/6909—Micelles formed by phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5184—Virus capsids or envelopes enclosing drugs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Genetics & Genomics (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Optics & Photonics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861852P | 2019-06-14 | 2019-06-14 | |
| US201962948095P | 2019-12-13 | 2019-12-13 | |
| PCT/US2020/037579 WO2020252375A1 (en) | 2019-06-14 | 2020-06-12 | Compositions and methods for biological delivery vehicles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL288755A true IL288755A (en) | 2022-02-01 |
Family
ID=73781318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL288755A IL288755A (en) | 2019-06-14 | 2021-12-07 | Compositions and methods for biological delivery vehicles |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220296516A1 (https=) |
| EP (1) | EP3982932A4 (https=) |
| JP (1) | JP7772597B2 (https=) |
| CN (1) | CN114286671A (https=) |
| AU (1) | AU2020290516B2 (https=) |
| CA (1) | CA3142949A1 (https=) |
| IL (1) | IL288755A (https=) |
| WO (1) | WO2020252375A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113166783B (zh) | 2018-10-09 | 2024-10-11 | 不列颠哥伦比亚大学 | 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法 |
| US20230023615A1 (en) * | 2019-12-13 | 2023-01-26 | Dnalite Therapeutics, Inc. | Compositions and methods for biological delivery vehicles |
| EP4259099A1 (en) * | 2020-12-14 | 2023-10-18 | Particella, Inc. | Biological delivery systems |
| WO2022260678A1 (en) * | 2021-06-11 | 2022-12-15 | Dnalite Therapeutics, Inc. | Compositions and methods for biological delivery vehicles |
| JPWO2022176953A1 (https=) * | 2021-02-17 | 2022-08-25 | ||
| WO2022211481A1 (ko) * | 2021-04-01 | 2022-10-06 | 에스엔제이 파마 인크 | 생활성물질의 경구용 나노입자 및 이의 제조방법 |
| KR102789632B1 (ko) * | 2021-04-01 | 2025-04-01 | 에스엔제이 파마 인크 | 생활성물질의 경구용 나노입자 및 이의 제조방법 |
| WO2023182812A1 (ko) * | 2022-03-22 | 2023-09-28 | 주식회사 바이오엔 | 담즙산염 및 양이온성 펩타이드를 포함하는 단백질 전달용 조성물 및 이의 용도 |
| CN117247359A (zh) * | 2022-06-09 | 2023-12-19 | 中国科学院广州生物医药与健康研究院 | 一种树状样脂质化合物、脂质体、脂质复合物、脂质纳米颗粒及其应用 |
| WO2024006863A1 (en) * | 2022-06-30 | 2024-01-04 | Precision NanoSystems ULC | Lipid nanoparticle formulations for vaccines |
| CN118356505A (zh) * | 2023-01-10 | 2024-07-19 | 复旦大学 | 含末端羟基的peg化纳米载体在制备规避人体预存抗peg抗体的药物制剂中的用途 |
| AU2023457271A1 (en) * | 2023-06-28 | 2025-12-18 | Global Life Sciences Solutions Canada Ulc | Lipid nanoparticle formulations for cell therapy and related methods |
| WO2025021286A1 (en) * | 2023-07-23 | 2025-01-30 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | A drug delivery system for increased endosomal escape |
| WO2025036297A1 (zh) * | 2023-08-11 | 2025-02-20 | 浙江海昶生物医药技术有限公司 | 一种具有靶向性的脂质组合物及其制备方法 |
| US20250082776A1 (en) * | 2023-08-31 | 2025-03-13 | Massachusetts Institute Of Technology | Polyanion coated lipid nanoparticles and methods of use thereof |
| PL248770B1 (pl) * | 2023-11-23 | 2026-01-26 | Politechnika Wroclawska | Bilosomy o dodatnim ładunku i sposób ich wytwarzania |
| WO2025151073A1 (en) * | 2024-01-10 | 2025-07-17 | Agency For Science, Technology And Research | Composition and nanoparticle suitable for use in the delivery of a therapeutic agent |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100817024B1 (ko) * | 2006-11-09 | 2008-03-26 | 재단법인 목암생명공학연구소 | 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물 |
| WO2010149785A1 (en) | 2009-06-26 | 2010-12-29 | Universiteit Gent | Cationic liposomes for the delivery of high molecular weight compounds |
| CA2784568A1 (en) | 2009-12-18 | 2011-06-23 | The University Of British Columbia | Lipid particles for delivery of nucleic acids |
| WO2012113803A1 (en) * | 2011-02-22 | 2012-08-30 | Leo Pharma A/S | A cyclic peptide and conjugate thereof for binding to keratinocytes |
| ES2929516T3 (es) * | 2014-10-31 | 2022-11-29 | Univ Utah Res Found | Composiciones y métodos para partículas con ácidos biliares |
| US11219634B2 (en) * | 2015-01-21 | 2022-01-11 | Genevant Sciences Gmbh | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells |
| BR112019008481A2 (pt) * | 2016-10-26 | 2020-03-03 | Curevac Ag | Vacinas de mrna de nanopartículas lipídicas |
| EP3558356A2 (en) * | 2016-12-23 | 2019-10-30 | CureVac AG | Mers coronavirus vaccine |
| WO2019046809A1 (en) * | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
-
2020
- 2020-06-12 AU AU2020290516A patent/AU2020290516B2/en active Active
- 2020-06-12 WO PCT/US2020/037579 patent/WO2020252375A1/en not_active Ceased
- 2020-06-12 US US17/619,036 patent/US20220296516A1/en active Pending
- 2020-06-12 JP JP2021573887A patent/JP7772597B2/ja active Active
- 2020-06-12 CA CA3142949A patent/CA3142949A1/en active Pending
- 2020-06-12 EP EP20821834.7A patent/EP3982932A4/en active Pending
- 2020-06-12 CN CN202080056429.6A patent/CN114286671A/zh active Pending
-
2021
- 2021-12-07 IL IL288755A patent/IL288755A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3142949A1 (en) | 2020-12-17 |
| CN114286671A (zh) | 2022-04-05 |
| JP2022538797A (ja) | 2022-09-06 |
| EP3982932A4 (en) | 2023-10-25 |
| AU2020290516A2 (en) | 2022-03-31 |
| EP3982932A1 (en) | 2022-04-20 |
| AU2020290516A1 (en) | 2022-01-20 |
| US20220296516A1 (en) | 2022-09-22 |
| JP7772597B2 (ja) | 2025-11-18 |
| WO2020252375A1 (en) | 2020-12-17 |
| AU2020290516B2 (en) | 2026-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288755A (en) | Compositions and methods for biological delivery vehicles | |
| IL281778A (en) | Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies | |
| IL283840A (en) | Compositions for the delivery of therapeutic agents and methods of use and making thereof | |
| IL288909A (en) | Methods of making bempedoic acid and compositions of the same | |
| IL270814A (en) | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer | |
| IL268788A (en) | Compositions and methods for enhanced gene expression | |
| IL259246A (en) | Compositions of therapeutic substances, methods and uses thereof | |
| IL269150A (en) | Compositions and methods for treating cancer | |
| IL281082A (en) | Compositions of cxcr4 inhibitors and methods of preparation and use | |
| IL281108A (en) | Compositions and methods for enhancing donor oligonucleotide-based gene editing | |
| EP3743069C0 (en) | BCL-2 PROTEIN-DEGRADING AGENTS FOR CANCER TREATMENT | |
| EP3471735A4 (en) | PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | |
| IL268814A (en) | Compositions and methods for treatment of cancer | |
| IL268872A (en) | Methods and compositions for treating cancers using antisense | |
| EP3595681A4 (en) | TRANSPLANT CELL-BASED IMMUNOTHERAPY FOR LONG-PERIOD ADMINISTRATION OF THERAPEUTIC PROTEIN | |
| IL281015A (en) | Methods and compositions for the modification of plants | |
| MA47119A (fr) | Livraison de protéines au moyen de bactéries à virulence atténuée | |
| IL282939A (en) | Mixtures and compositions comprising 5-fluoro-4-imino-3- methyl-1-tosyl-3,4- dihydropyrimidin-2-one, and methods of use thereof | |
| IL269157A (en) | Compositions and methods for treating cancer | |
| IL280348A (en) | Surface treatment compositions and methods | |
| IL282251A (en) | Compositions and methods for treatment of liver disease | |
| IL285039A (en) | Compositions and methods for stimulating natural killer cells | |
| IL286811A (en) | Compositions and methods for stabilizing protein-containing formulations | |
| IL287423A (en) | Antibodies and methods for treatment of influenza a infection | |
| IL264593A (en) | Pharmaceutical compositions comprising akt protein kinase inhibitors |